BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.
Karin Haraldsson(Lund University), Åke Borg(Lund University), Håkan Olsson(Nokia (Finland)), Qiuxia Zhang(Skåne University Hospital), Niklas Loman(Lund University), Óskar Þór Jóhannsson(National University Hospital of Iceland)
PubMed
April 1, 1998
Cited by 147
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
The Life History of 21 Breast Cancers
|Cell|2012|1.5k